“Patient satisfaction with tildrakizumab treatment in a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe plaque psoriasis”, J of Skin, vol. 7, no. 2, p. s134, Mar. 2023, doi: 10.25251/skin.7.supp.134.